Kazuya Kariyama

Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis

Atsushi Hiraoka, Takashi Kumada, Kunihiko Tsuji et al. · Liver Cancer · 2018 · 245 citations · Full text

Medicine, Oncology, Diagnostic Pathology +15

Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications

Atsushi Hiraoka, Takashi Kumada, Masatoshi Kudo et al. · Liver Cancer · 2017 · 213 citations · Full text

Medicine, Oncology, Clinical Epidemiology +15

Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Masanori Atsukawa et al. · Cancer Medicine · 2019 · 159 citations · Full text

Medicine, Oncology, Pharmacology +13

Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions: Multicenter analysis

Atsushi Hiraoka, Takashi Kumada, Kazuya Kariyama et al. · Cancer Medicine · 2018 · 132 citations · Full text

Medicine, Oncology, Pharmacology +15

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Margherita Rimini, Lorenza Rimassa, Kazuomi Ueshima et al. · ESMO Open · 2022 · 130 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14